BIOGEN INC.  AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)
## Table 0 ##
(1) Gross profit is calculated as total revenues less cost of sales, excluding amortization of acquired intangible assets.
(a) Net income and net income attributable to Biogen Inc. , for the third quarter of 2015, include a pre-tax charge to research and development expense of $48.1 million recorded upon entering into the collaboration agreement with AGTC.
(b) Net income attributable to Biogen Inc. , for the third quarter of 2015, reflects the attribution of a $60.0 million charge to noncontrolling interests, net of tax, related to a milestone payment due Neurimmune upon the enrollment of the first patient in a Phase 3 trial for aducanumab.
(c) Net income and net income attributable to Biogen Inc. , for the fourth quarter of 2015, include a pre-tax charge to research and development expense of $60.0 million recorded upon entering into the collaboration agreement with MTPC.
(d) Net income and net income attributable to Biogen Inc. , for the fourth quarter of 2015, include pre-tax restructuring charges totaling $93.4 million.
(e) Net income and net income attributable to Biogen Inc. , for the first quarter of 2014, include pre-tax charges to research and development expense of $117.7 million recorded upon entering into the collaboration agreement with Eisai.
(f) Product revenues, net and total revenues for the second, third and fourth quarters of 2014 include net revenues related to ALPROLIX as commercial sales of ALPROLIX commenced in the second quarter of 2014.
Product revenues, net and total revenues for the third and fourth quarters of 2014 include net revenues related to ELOCTATE and PLEGRIDY as commercial sales of ELOCTATE and PLEGRIDY commenced in the third quarter of 2014.
(g) Product revenues, net and total revenues for the second quarter of 2014 include the recognition of $53.5 million of revenue previously deferred in Italy relating to the pricing agreement with AIFA.
BIOGEN INC.  AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued) F- 77 contingent milestone payments are not considered contractual obligations as they are contingent on the successful achievement of certain development, regulatory approval or commercial milestones.
Other Funding Commitments As of December 31, 2018, we have several ongoing clinical studies in various clinical trial stages.
Our most significant clinical trial expenditures are to CROs.
The contracts with CROs are generally cancellable, with notice, at our option.
We recorded accrued expenses of approximately $27.0 million in our consolidated balance sheet for expenditures incurred by CROs as of December 31, 2018.
We have approximately $655.0 million in cancellable future commitments based on existing CRO contracts as of December 31, 2018.
Tax Related Obligations We exclude liabilities pertaining to uncertain tax positions from our summary of contractual obligations as we cannot make a reliable estimate of the period of cash settlement with the respective taxing authorities.
As of December 31, 2018, we have $117.7 million of liabilities associated with uncertain tax positions.
As of December 31, 2018 and 2017, we have accrued income tax liabilities of $697.0 million and $989.6 million, respectively, under the Transition Toll Tax.
Of the amounts accrued as of December 31, 2018, no amounts are expected to be paid within one year due to a $150.0 million overpayment of taxes in the current year.
The Transition Toll Tax will be paid over an eight-year period, which started in 2018, and will not accrue interest.
For additional information on the Transition Toll Tax, please read Note 17, Income Taxes, to these consolidated financial statements.
Solothurn, Switzerland Manufacturing Facility We are building a large-scale biologics manufacturing facility in Solothurn, Switzerland.
We expect this facility to be operational by the end of 2020.
As of December 31, 2018, we had contractual commitments of $111.0 million related to the construction of this facility.
Leases We rent laboratory and office space and certain equipment under non-cancelable operating leases.
These lease agreements contain various clauses for renewal at our option and, in certain cases, escalation clauses typically linked to rates of inflation.
Rental expense, net of sublease income under these leases, which terminate at various dates through 2028, amounted to $64.5 million, $65.3 million and $68.7 million in 2018, 2017 and 2016, respectively.
In addition to rent, the leases may require us to pay additional amounts for taxes, insurance, maintenance and other operating expenses.
As of December 31, 2018, minimum rental commitments under non-cancelable leases, net of income from subleases, for each of the next five years and total thereafter were as follows:
## Table 1 ##
(1) Represents sublease income expected to be received for the vacated manufacturing facility in Cambridge, MA, the vacated portion of our Weston, MA facility and other facilities throughout the world.
Under certain of our lease agreements, we are contractually obligated to return leased space to its original condition upon termination of the lease agreement.
At the inception of a lease with such conditions, we record an asset retirement obligation liability and a corresponding capital asset in an amount equal to the estimated fair value of the obligation.
In subsequent periods, for each such lease, we record interest expense to accrete the asset retirement obligation liability to full value and depreciate each capitalized asset retirement obligation asset, both over the term of the associated lease agreement.
Our asset retirement obligations were not significant as of December 31, 2018 or 2017.
Restructuring and Other Charges—Restructuring and other charges for each year in the three-year period ended December 31, 2015 were comprised of the following:
## Table 2 ##
Layoff costs were recorded based on approved detailed action plans submitted by the operating locations that specified positions to be eliminated, benefits to be paid under existing severance plans, union contracts or statutory requirements, and the expected timetable for completion of the plans.2015 Actions.
In 2015, Alcoa recorded Restructuring and other charges of $1,195 ($836 after-tax and noncontrolling interest), which were comprised of the following components: $438 ($281 after-tax and noncontrolling interest) for exit costs related to decisions to permanently shut down and demolish three smelters and a power station (see below); $246 ($118 after-tax and noncontrolling interest) for the curtailment of two refineries and two smelters (see below); $201 (pre- and after-tax) related to legal matters in Italy; a $161 ($151 after-tax and noncontrolling interest) net loss related to the March 2015 divestiture of a rolling mill in Russia (see Global Rolled Products in Segment Information below) and post-closing adjustments associated with three December 2014 divestitures; $143 ($102 after-tax and noncontrolling interest) for layoff costs, including the separation of approximately 2,100 employees (425 in the Transportation and Construction Solutions segment, 645 in the Engineered Products and Solutions segment, 380 in the Primary Metals segment, 90 in the Global Rolled Products segment, 85 in the Alumina segment, and 475 in Corporate); $34 ($14 after-tax and noncontrolling interest) for asset impairments, virtually all of which was related to prior capitalized costs for an expansion project at a refinery in Australia that is no longer being pursued; an $18 ($13 aftertax) gain on the sale of land related to one of the rolling mills in Australia that was permanently closed in December 2014 (see 2014 Actions below); a net charge of $4 (a net credit of $7 after-tax and noncontrolling interest) for other miscellaneous items; and $14 ($11 after-tax and noncontrolling interest) for the reversal of a number of small layoff reserves related to prior periods.
During 2015, management initiated various alumina refining and aluminum smelting capacity curtailments and/or closures.
The curtailments were composed of the remaining capacity at all of the following: the S?o Luís smelter in Brazil (74 kmt-per-year); the Suriname refinery (1,330 kmt-per-year); the Point Comfort, TX refinery (2,010 kmt-peryear); and the Wenatchee, WA smelter (143 kmt-per-year).
All of the curtailments were completed in 2015 except for 1,635 kmt-per-year at the Point Comfort refinery, which is expected to be completed by the end of June 2016.
The permanent closures were composed of the capacity at the Warrick, IN smelter (269 kmt-per-year) (includes the closure of a related coal mine) and the infrastructure of the Massena East, NY smelter (potlines were previously shut down in both 2013 and 2014—see 2013 Actions and 2014 Actions below), as the modernization of this smelter is no longer being pursued.
The shutdown of the Warrick smelter is expected to be completed by the end of March 2016.
The decisions on the above actions were part of a separate 12-month review in refining (2,800 kmt-per-year) and smelting (500 kmt-per-year) capacity initiated by management in March 2015 for possible curtailment (partial or full), permanent closure or divestiture.
While many factors contributed to each decision, in general, these actions were initiated to maintain competitiveness amid prevailing market conditions for both alumina and aluminum.
Demolition and remediation activities related to the Warrick smelter and the Massena East location will begin in 2016 and are expected to be completed by the end of 2020.
Separate from the actions initiated under the reviews described above, in mid-2015, management approved the permanent shutdown and demolition of the Po?os de Caldas smelter (capacity of 96 kmt-per-year) in Brazil and the

<table><tr><td>(In millions, except per share amounts)</td><td>FirstQuarter</td><td rowspan="2">SecondQuarter (f) (g)(f)</td><td>ThirdQuarter</td><td rowspan="2">FourthQuarter (f)</td><td>TotalYear</td></tr><tr><td>2014(e)</td><td></td><td></td><td></td></tr><tr><td>Product revenues, net</td><td>$1,742.8</td><td>$2,056.3</td><td>$2,117.3</td><td>$2,287.0</td><td>$8,203.4</td></tr><tr><td>Unconsolidated joint business revenues</td><td>$296.9</td><td>$303.3</td><td>$290.7</td><td>$304.5</td><td>$1,195.4</td></tr><tr><td>Other revenues</td><td>$90.1</td><td>$61.9</td><td>$103.4</td><td>$49.2</td><td>$304.5</td></tr><tr><td>Total revenues</td><td>$2,129.8</td><td>$2,421.5</td><td>$2,511.4</td><td>$2,640.7</td><td>$9,703.3</td></tr><tr><td>Gross profit -1</td><td>$1,850.5</td><td>$2,129.6</td><td>$2,208.8</td><td>$2,343.4</td><td>$8,532.3</td></tr><tr><td>Net income</td><td>$479.7</td><td>$723.1</td><td>$856.1</td><td>$882.6</td><td>$2,941.6</td></tr><tr><td>Net income attributable to Biogen Inc.</td><td>$480.0</td><td>$714.5</td><td>$856.9</td><td>$883.5</td><td>$2,934.8</td></tr><tr><td>Net income per share:</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Basic earnings per share attributable to Biogen Inc.</td><td>$2.03</td><td>$3.02</td><td>$3.63</td><td>$3.75</td><td>$12.42</td></tr><tr><td>Diluted earnings per share attributable to Biogen Inc.</td><td>$2.02</td><td>$3.01</td><td>$3.62</td><td>$3.74</td><td>$12.37</td></tr><tr><td>Weighted-average shares used in calculating:</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Basic earnings per share attributable to Biogen Inc.</td><td>236.8</td><td>236.7</td><td>236.2</td><td>235.5</td><td>236.4</td></tr><tr><td>Diluted earnings per share attributable to Biogen Inc.</td><td>237.8</td><td>237.4</td><td>237.0</td><td>236.3</td><td>237.2</td></tr></table>
<table><tr><td>(In millions)</td><td>2019</td><td>2020</td><td>2021</td><td>2022</td><td>2023</td><td>Thereafter</td><td>Total</td></tr><tr><td>Minimum lease payments</td><td>$87.0</td><td>$80.7</td><td>$75.9</td><td>$71.7</td><td>$71.0</td><td>$215.3</td><td>$601.6</td></tr><tr><td>Less: income from subleases -1</td><td>-26.8</td><td>-25.6</td><td>-23.7</td><td>-24.0</td><td>-24.3</td><td>-58.4</td><td>-182.8</td></tr><tr><td>Net minimum lease payments</td><td>$60.2</td><td>$55.1</td><td>$52.2</td><td>$47.7</td><td>$46.7</td><td>$156.9</td><td>$418.8</td></tr></table>
<table><tr><td></td><td>2015</td><td>2014</td><td>2013</td></tr><tr><td>Asset impairments</td><td>$335</td><td>$406</td><td>$116</td></tr><tr><td>Layoff costs</td><td>299</td><td>259</td><td>201</td></tr><tr><td>Legal matters in Italy</td><td>201</td><td>-</td><td>-</td></tr><tr><td>Net loss on divestitures of businesses</td><td>161</td><td>332</td><td>-</td></tr><tr><td>Resolution of a legal matter</td><td>-</td><td>-</td><td>391</td></tr><tr><td>Other</td><td>213</td><td>199</td><td>82</td></tr><tr><td>Reversals of previously recorded layoff and other exit costs</td><td>-14</td><td>-28</td><td>-8</td></tr><tr><td>Restructuring and other charges</td><td>$1,195</td><td>$1,168</td><td>$782</td></tr></table>

Question: what is the highest total amount of Product revenues, net in 2014?? (in million)
Answer: 16406.8